Clinical Trials

Provider wearing a mask working on a computer

Clinical trials test new drugs and new ways of treating patients with lymphoma. Our experts conduct these studies to find better treatments. Many clinical trials become the next standard of care. To determine if a trial is right for you, make an appointment for a consultation at 410.955.8964.

Curent Lymphoma Clinical Trials

A105: Multicenter, open-label feasibility study of Daratumumab with dose-adjusted EPOCH in newly diagnosed plasmablastic Lymphoma (Sponsor: NCI, AMC-105)

EA4181: A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma (Sponsor: ETCTN EA4181)

J18106: A phase I/Ib multicenter study to evaluate the humanized anti-CD 73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with Pembrolizumab in adult subjects with advanced cancers (CPI-006-001)

J18144: Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer (FLX475-02)

J18168: A phase Ib open-label study to evaluate the safety and antitumor activity of Loncastuximab Tesirine and Ibrutinib in patients with advanced diffuse large B-cell lymphoma or mantle cell lymphoma (Sponsor: ADC Therapeutics)

J2128: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)

J2158: Phase III Study Evaluating Glofitamab in Combination with Gemcitabine plus Oxaliplatin versus Ritxumab in patients with Relasped/Refractory Diffuse Large B-Cell Lymphoma (Sponsor: Imcore - Genentech GO41944)

NCTCNA051701: Randomized Phase II / III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC / BCL2 Double Hit and Double Expressing Lymphomas (Sponsor: NCTN: A051701)

NCTCNGY022 NRG-GY022: Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin

PANHL1931: A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma (Sponsor: COG)

S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (age >/= 12) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (Sponsor: NCTN: S1826)

Clonal evolution in follicular lymphoma (Sponsor: NIH/NCI)

Search All Cancer Clinical Trials